ORTHOFIX MEDICAL INC
OFIXNASDAQTrading Snapshot
- Day Range
- $9.68 β $9.92
- 52-Week Range
- $8.50 β $16.99
- Volume
- $2.02B
- Avg Volume
- $2.55B
- Shares Outstanding
- 40.4M
- Next Earnings
- Nov 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $822M
- Last Q Revenue
- $211M
- P/E Ratio
- β
- P/S Ratio
- 0.5x
- EPS (TTM)
- $-1.53
- Dividend Yield
- β
- Dilution (1yr)
- +3.4%
Why Investors Own OFIX
- βHigh-growth profile β revenue up +1.2% YoY with expanding US Equity exposure.
- βHealthy economics β 61% gross margin and 14% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ORTHOFIX MEDICAL INC
OFIXAbout ORTHOFIX MEDICAL INC
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates

Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook
Orthofix Medical NASDAQ: OFIX executives said the company's updated outlook reflects the restoration of bone growth stimulation reimbursement, improving trends in biologics and limb reconstruction, and an expected Europe

Orthofix Medical Q2 Earnings Call Highlights
Orthofix Medical NASDAQ: OFIX reported second-quarter results that management said reflected improving operating trends across several businesses, while continued weakness among smaller U.S. spine distributors remained a

Orthofix Medical Inc. (OFIX) Q2 2026 Earnings Call Transcript
Orthofix Medical Inc. (OFIX) Q2 2026 Earnings Call Transcript

Bet on 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Orthofix (OFIX) Q2 Earnings and Revenues Surpass Estimates
Orthofix (OFIX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to earnings of $0.13 per share a year ago.

Orthofix Reports Second Quarter 2026 Results Reflecting Continued Operational Progress
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the second quarter ended June 30, 2026, reflecting progress t